Compositions and methods are provided for rapid and efficient production of antibodies in vitro as well as in vivo, which may be used to neutralize antigens. More specifically, the present invention relates to scaffolds comprised of amphiphilic multiblock copolymers that can form micelles based on nonionic or amphiphilic core blocks as well as ionic blocks, and with an antigen and methods of crosslinking B cell receptors to specifically produce antibodies against the antigen in vitro as well as in vivo in a more efficient method than other available monoclonal antibody production method.

Disclosed are media, methods, systems and kits for differentiating hematopoietic progenitor cells from a population of early mesoderm cells under conditions that exclude any combination of certain exogenously added agonists of growth factor signaling. The population of early mesoderm cells may be derived from pluripotent stem cells, and the hematopoietic progenitor cells differentiated under the disclosed conditions are multipotent. The culture conditions disclosure herein may form serum-free workflows and/or workflows free of stroma and/or feeder cells.

Herein is reported an antibody binding to rabbit CD19 comprising (a) a HVR-H1 comprising the amino acid sequence of SEQ ID NO: 32 or 33 or 34, (b) a HVR-H2 comprising the amino acid sequence of SEQ ID NO: 35 or 36, (c) a HVR-H3 comprising the amino acid sequence of SEQ ID NO: 37, (d) a HVR-L1 comprising the amino acid sequence of SEQ ID NO: 38, (e) a HVR-L2 comprising the amino acid sequence of SEQ ID NO: 39, and (f) a HVR-L3 comprising the amino acid sequence of SEQ ID NO: 40, as well as methods of using the same, especially in the identification and selection of antibody producing rabbit B-cells.

This invention provides methods for diagnosing Alzheimer's disease in a symptomatic human subject. These methods comprise measuring the growth rate, size and/or protein amount of a subject's skin fibroblasts and/or lymphocytes, and determining whether these values differ in certain ways from those of corresponding non-Alzheimer's disease dementia cells. This invention also provides methods for determining whether an asymptomatic human subject is at risk from becoming afflicted with Alzheimer's disease.

A fluidic system for producing extracellular vesicles from suspended producer cells, including at least one container, a liquid medium contained in the container, suspended producer cells, a liquid medium agitator, a device for controlling the speed of the agitator suitable for the growth of the suspended producer cells, wherein the device for controlling the speed of the agitator, the agitator and the shape and dimensions of the container are suitable for generating a turbulent flow of the liquid medium in the container for exerting shear stresses on the producer cells in order to carry out the production of extracellular vesicles, the Kolmogorov length of the flow being less than or equal to 50 μm.

The present invention provides improved and/or shortened processes and methods for preparing TILs in order to prepare therapeutic populations of TILs with increased therapeutic efficacy for the treatment of non-small cell lung carcinoma (NSCLC), wherein the NSCLC is refractory to treatment with an anti-PD-1 antibody.

The present invention relates to a topical pharmaceutical preparation for treating an inflammatory skin condition, preferably a condition associated with ischemia, comprising a supernatant of a physiological solution obtainable by cultivating peripheral blood mononuclear cells (PBMCs) or a subset thereof in a physiological solution free of PBMC-proliferating and PBMC-activating substances for at least 1 h.

Provided herein are methods and systems for bio-printing of three-dimensional organs and organoids. Also provided herein are bio-printed three-dimensional organs and organoids for use in the generation and/or the assessment of immunological products and/or immune responses. Also provided herein are methods and system for bio-printing three-dimensional matrices.

The present invention relates to compounds for use in treating a disease that is associated with (related to) CYP7B1 wherein the compound inhibits CYP7B1. The present invention further relates to a method of treating or preventing such a disease by administering an inhibitor of CYP7B1. The present invention also relates to a method of determining whether a compound is effective in treating or preventing a disease associated with the formation of inducible bronchus-associated lymphoid tissue (iBALT).

Described herein are methods and compositions for modifying a mammalian cell plasma membrane to retain secreted antibodies, capturing antibodies produced by the cells and sorting antibody producing cells according to antibody specificities or antibody quantities. These methods and compositions may be particularly useful for biological and medical applications. The methods may include modifying cell membranes from a population of antibody producing cells by inserting a membrane anchor into the cell membranes, a generic antibody capture molecule attached to the cell anchor, capturing antibodies produced by the cell, and detecting and dispending cells according to antibody specificities or antibody quantities with a microparticle sorting and dispensing apparatus.